An INS1007 Phase III program in Non Cystic Fibrosis Bronchiectasis
Brief description of study
The purpose of this study is to evaluate the efficacy, safety, and tolerability of brensocatib as treatment for non-cystic fibrosis bronchiectasis (NCFBE). Brensocatib is an experimental drug. “Experimental” means that the study drug is currently being tested in clinical research studies, and has not been approved by the United States Food and Drug Administration (FDA) for use in the treatment of patients with NCFBE.
Clinical Study Identifier: s19-01987
ClinicalTrials.gov Identifier: NCT04594369
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
